PFOS, acide, sels et dérivés. INERIS, 2012. Données technico-économiques sur les substances chimiques en France : DRC-12-126866- 07631A, 89 p. (www.rsde.ineris.fr/ ou www.ineris.fr/substances/fr/).
G, Chavroche J, Dupoiron B - Composés perfluorés : évaluation et gestion des risques liés au PFOS. ENSP Rennes, 2005.
Perfluorooctane sulfonate (PFOS) and its salts. OECD Hazard assessment. 2002.
PFOS. Fiche de données de sécurité, Sigma-Aldrich, 2012.
Johnson JD et Ober RE - Absorption of FC-95-14C in rats after a single oral dose. US EPA, 1979.
Johnson JD, Gibson SJ et Ober RE - Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. Fundam Appl Toxicol. 1984 ; 4(6) : 972-976.
3M Company - Determination of serum half-lives of several fluoroche- micals, supplemental submission. St Paul, MN. 2000.
Olsen GW, Huang HY, Helzlsouer KJ et al. - Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ Health Perspect. 2005 ; 113(5) : 539-545.
Chang SU, Noker PE, Gorman GS, Gibson SJ et al. - Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice and monkeys. Reprod Toxicol. 2012 ; 33 : 428-440.
Maestri L, Negri S, Ferrari M et al. - Determination of perfluorooctanoic acid and perfluorooctanesulfonate in human tissues by liquid chromatography/single quadrupole mass spectrometry. Rapid Commun Mass Spectrom. 2006 ; 20 : 2728-2734.
Emond C et Restieri C - Les caractéristiques pharmacocinétiques des perfluorés. Bulletin de veille scientifique n° 15. ANSES, 2011.
Austin ME, Kasturi BS, Barber M, Kannan K et al. - Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ Health Perspect. 2003 ; 111(12) : 1485-1489.
Bogdanska J, Borg D, Sundstrom SM, Bergstrom U et al. - Tissue distribution of35S-labelled perfluorooctane sulfonate in adult mice after oral exposure to a low environmentally relevant dose or a high experimental dose. Toxicology. 2011 : 54-62.
Borg D, Bogdanska J, Sundstrom M, Nobel SM et al. - Tissue distribution of 35S-radiolabelled perfluorooctane sulfonate (PFOS) in C57BI/6 mice following late gestational exposure. Reprod Toxicol. 2010 ; 30 : 558-565.
Avis de l'Agence française de sécurité sanitaire des aliments relatif aux risques potentiels pour la santé humaine liés à la présence résiduelle d'acide perfluorooctanoïque (PFOA) dans les revêtements antiadhésifs des ustensiles de cuisson des aliments. AFSSA, 2009.
Lau C, Anitole K, Hodes C, Lai D et al. - Perfluoroalkyl acids: A review of monitoring and toxicological findings. Toxicol Sci. 2007 ; 99 (2) : 366-394.
NHANES. Fourth National Report on Human Exposure, Updated tables, CDC. , March 2013, 318 p.
Schulz C, Wilhelm M, Hudorf U, Kolossa-Gehring M - Update of the reference and HBM values derived by the German Human Biomonitoring Commission. Int. J. Hyg. Environ. Health. 2011 ; 215 : 26-35.
Perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts Scientific opinion of the panel on contaminants in the food chain. The EFSA Journal. 2008 ; 653 : 79-131.
Deutsche Forschungsgemeinschaft (DFG) - List of MAK and BAT values 2012. Maximum concentrations and biological tolerance values at the workplace. Report 48. Weinheim : Wiley-VCH Verlag ; 2012 : 259 p.
Dean WP, Jessup DC, Thompson G, Romig G et Powell D - Fluorochemical surfactant FC-95 acute oral toxicity (LD50) study in rats. International Research and Development Corporation. Mattawan, MI. 1978.
Rusch GM, Rinehart WE et Bozak CA - An acute inhalation toxicity study of T-2306 CoC in the rat. Bio/dynamics Inc, Thomford. 1979.
Biesemeier JA et Harris DL - Eye and skin irritation report on sample T- 1117. WARF Institute Inc, Brown. 1974.
Kim HS, Kwack SJ, Han ES, Kang TS et al. - Induction of apoptosis and CYP4A1 expression in Sprague-Dawley rats exposed to low doses of perfluorooctane sulfonate. J Toxicol Sci. 2011 ; 36(2) : 201-210.
Butenhoff JL, Chang SC, Olsen GW et Thomford PJ - Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague-Dawley rats. Toxicology. 2012 ; 293 : 1-15.
Elcombe CR, Elcombe BM, Foster J, Chang S et al. - Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology. 2012 ; 293 : 30-40.
Bjork JA, Butenhoff JL et Wallace KB - Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology. 2011 ; 288 : 8-17.
Haughom B et Spydevold O - The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta. 1992 ; 1128(1) : 65 72.
Seacat AM, Thomford PJ, Hansen KJ, Clemen LA et al. - Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology. 2003 ; 183(1-3) : 117-131.
Thomford PJ - 104-week dietary chronic toxicity and carcinogenicity study with perfluorooctanoate sulfonic acid potassium salt (PFOS; T- 6295) in rats. St Paul, MN. 2002.
Wan HT, Zhao YG, Wei X, Hui KY et al. - PFOS-induced hepatic steatosis, the mechanistic actions on µ-oxidation and lipid transport. Biochim Biophys Acta. 2012 ; 1820 : 1092-1101.
Seacat AM, Thomford PJ, Hansen KJ, Olsen GW et al. - Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci. 2002 ; 68(1) : 249-264.
Thomford PJ - 4-week capsule toxicity study with perfluorooctane sulfonic acid potassium salt (PFOS; T-6295) in Cynomolgus monkeys. St Paul, MN. 2002.
Qazi MR, Nelson BD, DePierre JW et Adebi-Valigerdi M - High-dose dietary exposure of mice to perfluorooctanoate or perfluorooctane sulfonate exerts toxic effects on myeloid and B-lymphoid cells in the bone marrow and these effects are partially dependent on reduced food consumption. Rood Chem Toxicol. 2012 ; 50 : 2955-2963.
DeWItt J, Peden-Adams M, Keller J et Germolec D - Immunotoxicity of perfluorinated compounds: recent developments. Toxicol Pathol. 2012 ; 40 : 300-311.
Litton Bionetics Inc - Mutagenicity evaluation of T-2014 CoC in the Ames Salmonelle/Microsome plate test. Final report, 1979.
Mecchi MS - Salmonella-Escherichia coli / Mammalian microsome reverse mutation assay with PFOS. Final report. Covance Laboratories. Vienna, VI. 1999.
Murli H - Chromosomal Aberrations in Human Whole Blood Lymphocytes with PFOS. Final Report. Covance Laboratories Inc. Vienna, VI. 1999.
Cifone MA - Unscheduled DNA synthesis in rat liver primary cell cultures with PFOS. Covance Laboratories Inc. Vienna, VI. 1999.
Jacquet N, Maire MA, Landkocz Y et Vasseur P - Carcinogenic potency of perfluorooctane sulfonate (PFOS) on Syrian hamster embryo (SHE) cells. Arch Toxicol. 2012 ; 86 : 305-314.
Murli H - Mutagenicity test on T-6295 in an in vivo mouse micronucleus assay. Final report. Corning Hazleton Inc. Vienna, VI. 1996.
Reistad T, Fonnum F et Mariussen E - Perfluoroalkylated compounds induce cell death and formation of reactive oxygen speciesin cultured cerebellar granule cells. Toxicol Lett. 2013 ; 218 : 56-60.
Chen T, Zhang L, Yue J, Lv Z et al. - Prenatal PFOS exposure induces oxidative stress and apoptosis in the lung of rat off-spring. Reprod Toxicol. 2012 ; 33 : 538-545.
Elcombe CR, Elcombe BM, Foster JR, Chang S et al. - Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARa and CAR/PXR. Toxicology. 2012 ; 293 : 16-29.
Luebker DJ, Case MT, York RG, Moore JA et al. - Two-generation reproduction and cross-foster studies of perfluorooctanesulfonate (PFOS) in rats. Toxicology. 2005 ; 215(1-2): 126-148.
Luebker DJ, York RG, Hansen KJ, Moore JA et Butenhoff JL - Neonatal mortality from in utero exposure to perfluorooctanesulfonate (PFOS) in Sprague-Dawley rats: dose-response, and biochemical and pharmacokinetic parameters. Toxicology. 2005 ; 215 (1-2) : 149-169.
Thibodeaux JR, Hanson RG, Rogers JM, et al. - Exposure to perfluorooc- tane sulfonate during pregnancy in rat and mouse. I : Maternal and prenatal evaluations. Toxicol Sci. 2003 ; 74(2) : 369-381.
Wetzel LT - Rat teratology study, Final report. Hazelton Laboratories America Inc. 1983.
Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE - Exposure to per- fluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol Sci. 2003 ; 74(2) : 382-392.
Christian MS - Oral (stomach tube) Developmental Toxicity Study of PFOS in Rabbits. Argus Research Laboratories, Inc. 1999
Christian MS - Combined oral (gavage) fertility, developmental and perinatal/postnatal reproduction toxicity study of PFOS in Rats. Argus Research Laboratories, Inc. 1999.
Christian MS - Oral (gavage) Cross-Fostering Study of PFOS in Rats Testing Facility. Argus Research Laboratories, Inc. 1999.
Fuentes S, Colomina MT, Vicens P et Domingo JL - Influence of maternal restraint stress on the long-lasting effects induced by prenatal exposure to perfluorooctane sulfonate (PFOS) in mice. Toxicol Lett. 2007 ; 171(3) : 162-170.
Fuentes S, Vicens P, Colomina MT et Domingo JL - Behavioral effects in adult mice exposed to perfluorooctane sulfonate (PFOS). Toxicology. 2007 ; 242(1-3) : 123-129.
Johansson N, Fredriksson A et Eriksson P - Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. Neurotoxicology. 2008 ; 29 : 160169.
Keil DE, Mehlmann T, Butterworth L et Peden-Adams MM - Gestational exposure to perfluorooctane sulfonate suppresses immune function in B6C3F1 mice. Toxicol Sci. 2008; 103(1) : 77-85.
Grice MM, Alexander BH, Hoffbeck R et Kampa DM - Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J. Occup. Environ. Med. 2007; 49(7) : 722-729.
Olsen GW, Burlew MM, Marshall JC, Burris JM, Mandel JH - Analysis of episodes of care in a perfluorooctanesulfonyl fluoride production facilitations. J. Occup. Environ. Med. 2004 ; 46(8) : 837-846.
Olsen GW, Burris JM, Burlew MM, Mandel JH - Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 2003 ; 45(3) : 260-270.
Olsen GW, Ehresman DJ, Buehrer BD, Gibson BA, Butenhoff JL et al. - Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities. JOEM. 2012 ; 54(8) : 974-983.
Knox S, Jackson T, Frisbee JS, Javins B et al. - Perfluorocarbons exposure, gender and thyroid function in the C8 health project. J. Toxicol. Sci. 2011 ; 36(4) : 403-410.
Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS - Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Env Health Perspective. 2010 ; 118(5) : 686-692.
Ji K, Kim S, Kho Y, Paek D, Sakong J et al. - Serum concentrations of major perfluorinated compounds among the general population in Korea: dietary sources and potential impact on thyroid hormones. Env. International. 2012 ; 45 : 78-85.
Knox S, Jackson T, Javins B, Frisbee JS et al. - Implications of early menopause in women exposed to perfluorocarbons. J. Clin. Endocrinol. Metab. 2011 ; 96 : 1747-1753.
Joensen UN, Veyrand B, Antignac JP, Blomberg Jensen M, et al. - PFOS (perfluorooctanesulfonate) in serum is negatively associated with testosterone levels, but not with semen quality, in healthy men. Hum. Reprod. 2013 ; 28(3) : 599-608.
Alexander BH, Olsen GW, Burris JM, Mandel JH et Mandel JS - Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 2003 ; 60(10) : 722-729.
Alexander BH, Olsen GW - Bladder cancer in perfluorooctanesulphonyl fluoride manufacturing workers. Ann. Epidemiol. 2007 ; 17 : 471-478.
Bonefeld-Jorgensen, Long M, Bossi R, Ayotte P et al. - Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: A case control study. Environmental Health. 2011 ; 10 : 88.
Toft G, Jönsson BA, Lindh CH, Giwercman A, Spano M, et al. - Exposure to perfluorinated compounds and human semen quality in arctic and European populations. Hum. Reprod. 2012 ; 27(8) : 2532-2540.
Vestergaard S, Nielsen F, Andersson AM, Hj0llund NH, Grandjean P et coll. - Association between perfluorinated compounds and time to pregnancy in a prospective cohort of Danish couples attempting to conceive. Hum. Reprod. 2012 ; 27(3) : 873-880.
Fei C, McLaughlin JK, Lipworth KL et Olsen J - Maternal levels of perfluorinated chemicals and subfecondity. Human Reproduction. 2009 ; 24(5) : 1200-1205.
Olsen GW, Butenhoff JL, Zobel LR - Perfluoroalkyl chemicals and human fetal development: an epidemiological review with clinical and toxicological perspectives. Reproductive Toxicology. 2009 ; 27 : 212-230.
Andersen CS, Fei C, Gamborg M, Nohr EA, S0rensen TI, Olsen J - Prenatal exposures to perfluorinated chemicals and anthropometric measures in infancy. Am. J. Epidemiol. 2010 ; 172(11) : 1230-1237.
Chen MH, Ha EH, Wen TW, Su YN, Lien GW et al. - Perfluorinated compounds in umbilical cord blood and adverse birth outcomes. PLoS ONE. 2012 ; 7(8) : 1-7.
Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU et al. - Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. Environ. Health Perspect. 2007 ; 115(11) : 1670-1676.
Washino N, Saijo Y, Sasaki S, Kato S, Ban S et al. - Correlations between prenatal exposure to perfluorinated chemicals and reduced fetal growth. Environ. Health Perspect. 2009 ; 117(4) : 660-667.
Fei C, McLaughlin JK, Tarone RE et Olsen J - Perfluorinated chemicals and fetal growth: a study within the Danish National Birth Cohort. Environ. Health Perspect. 2007 ; 115(11) : 1677-1682.
Fei C, McLaughlin JK, Tarone RE et Olsen J - Fetal growth indicators and perfluorinated chemicals: a study in the Danish National Birth Cohort. Am. J. Epidemiol. 2008 ; 168(1): 66-72.
Inoue K, Okada F, Ito R, Kato S, Sasaki S et al. - Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ. Health Perspect. 2004 ; 112(11) : 12041207.
Fei C, Olsen J - Prenatal exposure to perfluorooctanoate chemicals and behavioral or coordination problems at age 7 years. Environ. Health Perspect. 2011 ; 119 : 573-578.
Cuves et réservoirs - Recommandation CNAMTS R 435. Paris : INRS ; 2008.
